Press releases
2004
11-09-2004
Revenue increase of 51 per cent in Q3 2004
Readjustment of revenue and earnings forecast for 2004Kleinostheim, November 9, 2004 – curasan AG (WKN 549 453) today announced its preliminary results for the first nine months ended September 30, 2004. As regards year-on-year comparisons, it should be noted that the Pharmaceuticals business unit (Anti-Infectives and AIEP products) was sold by the company in October 2003 and that curasan is currently focusing on the area of Regenerative Medicine ...
08-12-2004
curasan AG: first-half results confirm strategic focus
Kleinostheim, August 12, 2004 – curasan AG (WKN 549 453) today announced its financial results for the first six months ended June 30, 2004. In terms of year-on-year comparisons, it should be noted that the Pharmaceuticals business unit (Anti-Infectives and AIEP products) was sold by the company in October 2003 and that curasan is now focusing on the area of Regenerative Medicine ...07-12-2004
curasan AG: Sales agreement with Ascension Orthopedics
curasan attracts new partner for US distribution
Kleinostheim/Austin, July 12, 2004 – curasan AG (WKN 549 453) has signed an exclusive agreement with Ascension Orthopedics, Inc., Austin/Texas (USA), for the distribution of Cerasorb® Ortho ...05-13-2004
curasan AG: strong growth in first quarter
Focus on regenerative medicine bears fruit Kleinostheim, May 13, 2004 - curasan AG (WKN 549 453) today announced its financial results for the first quarter ended March 31, 2004. Year-on-year comparisons must take into account that the Pharmaceuticals business unit (Anti-Infectives and AIEP products) was sold by the company in November 2003 ...03-17-2004
Change in Management Board of curasan AG
Kleinostheim, 17 March 2004 - At the personal request of Mr. Helmut Trahmer and with the consent of the Supervisory Board his contract as Chief Financial Officer due to end on 31 December 2004 was terminated by mutual agreement and on friendly terms effective 31 March 2004 ...02-25-2004
curasan AG announces preliminary results for 2003
Revenues from 14.7 to 15 Mio. EUR, net profit from - 2.3 to about + 3 Mio. EUR Kleinostheim, February 25, 2004 - curasan AG (WKN 549 453) today announced its preliminary results for the financial year ended December 31, 2003. Management anticipates total revenues of EUR 15 million for the period (2002: EUR 14.7 million) ...02-17-2004
curasan: launch of the anti-cancer drug Mitem® on the German market
Hoyer-Madaus holds exclusive distribution rights
Kleinostheim/Monheim, 17 February 2004 - curasan AG (WKN: 549 453) has awarded exclusive distribution rights for Mitem® (Mitomycin) to urology specialists Hoyer-Madaus GmbH & Co KG for a minimum period of eight years ...01-23-2004
curasan AG: Market Launch of Curavisc®
Kleinostheim/Barneveld (NL), 23 January 2004 - Curavisc®, a product for the treatment of osteoarthrosis manufactured fermentatively by IDT GmbH, has now received CE certification and is authorised for sale in the European orthopaedic market. Exclusive distribution rights are held by curasan Benelux B.V. (a wholly owned subsidiary of curasan AG) ...01-13-2004
curasan: FDA approval for Cerasorb®DENTAL - sales organization established
Only resorbable ß-TCP bone regeneration material within US dental marketKleinostheim, 13 January 2004 - The synthetic bone regeneration material Cerasorb®DENTAL, developed by curasan AG (WKN 549 453), is available for distribution within the US dental sector following a PMA (Premarket Approval) issued by the Food and Drug Administration (FDA) ...